Literature DB >> 28218413

Minimal clinically important differences for the experiences of daily living parts of movement disorder society-sponsored unified Parkinson's disease rating scale.

Krisztina Horváth1, Zsuzsanna Aschermann1,2, Márton Kovács1,2, Attila Makkos1,2, Márk Harmat1,2, József Janszky2,3, Sámuel Komoly2, Kázmér Karádi1,4, Norbert Kovács2,3.   

Abstract

BACKGROUND: The minimal clinically important difference is the smallest change of scores clinically meaningful to patients.
OBJECTIVES: We aimed to calculate these threshold values in association with the International Parkinson and Movement Disorder Society UPDRS (MDS-UPDRS) Parts I and II and to evaluate the feasibility of the composite score of Part I and II (MDS-UPDRS I+II) as an outcome.
METHODS: Nine hundred eighty-five paired investigations of 365 patients were reviewed, implementing three different techniques simultaneously.
RESULTS: Based on the ordinal regression modeling, the MDS-UPDRS I+II score is an applicable outcome measure. Any improvement greater than 2.64 points or any worsening more than 2.45 points on MDS-UPDRS Part I represent a minimal, yet clinically meaningful change. In reference to Part II, the smallest changes considered clinically relevant were 3.05 and 2.51 points for improvement and deterioration, respectively. The thresholds for MDS-UPDRS I+II were 5.73 points for improvement and 4.70 points for worsening.
CONCLUSIONS: Our minimal clinically important difference thresholds can be utilized in clinical practice in judging clinical relevance.
© 2016 International Parkinson and Movement Disorder Society. © 2017 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  UPDRS; minimal but clinically relevant differences; minimal clinically important changes; patient reported outcomes; receiver operating characteristic curve

Mesh:

Year:  2017        PMID: 28218413     DOI: 10.1002/mds.26960

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  16 in total

1.  Efficacy and evaluation of therapeutic exercises on adults with Parkinson's disease: a systematic review and network meta-analysis.

Authors:  Yong Yang; Guotuan Wang; Shikun Zhang; Huan Wang; Wensheng Zhou; Feifei Ren; Huimin Liang; Dongdong Wu; Xinying Ji; Makoto Hashimoto; Jianshe Wei
Journal:  BMC Geriatr       Date:  2022-10-21       Impact factor: 4.070

2.  Prevalence of Anxiety among Hungarian Subjects with Parkinson's Disease.

Authors:  Márton Kovács; Attila Makkos; Rita Weintraut; Kázmér Karádi; József Janszky; Norbert Kovács
Journal:  Behav Neurol       Date:  2017-09-26       Impact factor: 3.342

3.  Low-fat versus ketogenic diet in Parkinson's disease: A pilot randomized controlled trial.

Authors:  Matthew C L Phillips; Deborah K J Murtagh; Linda J Gilbertson; Fredrik J S Asztely; Christopher D P Lynch
Journal:  Mov Disord       Date:  2018-08-11       Impact factor: 10.338

Review 4.  Update on the Management of Parkinson's Disease for General Neurologists.

Authors:  Zvezdan Pirtošek; Ovidiu Bajenaru; Norbert Kovács; Ivan Milanov; Maja Relja; Matej Skorvanek
Journal:  Parkinsons Dis       Date:  2020-03-26

5.  Fast 3 T nigral hyperintensity magnetic resonance imaging in Parkinson's disease.

Authors:  Gabriella Hernadi; David Pinter; Szilvia Anett Nagy; Gergely Orsi; Samuel Komoly; Jozsef Janszky; Norbert Kovacs; Gabor Perlaki
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

6.  Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson's Disease and Dyskinesia.

Authors:  Shyamal H Mehta; Rajesh Pahwa; Caroline M Tanner; Robert A Hauser; Reed Johnson
Journal:  Neurol Ther       Date:  2021-04-17

7.  Does Subthalamic Deep Brain Stimulation Impact Asymmetry and Dyscoordination of Gait in Parkinson's Disease?

Authors:  Deepak K Ravi; Christian R Baumann; Elena Bernasconi; Michelle Gwerder; Niklas K Ignasiak; Mechtild Uhl; Lennart Stieglitz; William R Taylor; Navrag B Singh
Journal:  Neurorehabil Neural Repair       Date:  2021-09-22       Impact factor: 3.919

8.  Real-World Nonmotor Changes in Patients with Parkinson's Disease and Motor Fluctuations: J-FIRST.

Authors:  Hirohisa Watanabe; Hidemoto Saiki; Shih-Wei Chiu; Takuhiro Yamaguchi; Kenichi Kashihara; Yoshio Tsuboi; Masahiro Nomoto; Nobutaka Hattori; Tetsuya Maeda; Yasushi Shimo
Journal:  Mov Disord Clin Pract       Date:  2020-04-11

Review 9.  Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson's Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer.

Authors:  Marie-Louise Zeissler; Vivien Li; Mahesh K B Parmar; Camille Buchholz Carroll
Journal:  J Parkinsons Dis       Date:  2020       Impact factor: 5.568

10.  Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson's Patients Using Digital Mobility Outcomes.

Authors:  Marco Viceconti; Sabina Hernandez Penna; Wilhelmus Dartee; Claudia Mazzà; Brian Caulfield; Clemens Becker; Walter Maetzler; Judith Garcia-Aymerich; Giorgio Davico; Lynn Rochester
Journal:  Sensors (Basel)       Date:  2020-10-20       Impact factor: 3.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.